top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 4 hours ago
  • 1 min read

19/02/2026

















AstraZeneca’s Saphnero was approved in Japan for patients with Systemic Lupus Erythematosus (Ref)


AstraZeneca announced that Japan had approved Saphnero (aniflorumab; anti-IFN1R) subcutaneous injection 120 mg autoinjector for the treatment of patients with Systemic Lupus Erythematosus (SLE)


  • This approval by the Ministry of Health, Labour and Welfare was based on the results from the Phase 3 TULIP SC/ NCT04877691 trial


  • In the TULIP SC trial the primary endpoint BICLA response rate at week 52 was achieved by 56.2%of patients in Saphnero SC group and 37.1% in the placebo group


  • Saphnero subcutaneous injection was generally well tolerated, and its safety profile was consistent with that of Saphnero intravenous infusion

bottom of page